Date updated:01-14-2008
No description available

-
TEVA
Teva Pharmaceutic - $52.03
- +0.79%
- $51.58
generic pharmaceutical products

-
BIIB
Biogen Idec Inc - $45.76
- +3.09%
- $44.13
Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies primarily in the areas of oncology, neurology, and immunology in the United States and internationally

-
XBI
Spdr S&p Biotech - $49.82
- +0.69%
- $49.12
SPDR S&P Biotech

-
MYGN
Myriad Genetics - $24.38
- -0.08%
- $24.24
Myriad Genetics, Inc., a biotechnology company, engages in the development and marketing of therapeutic and molecular diagnostic products

-
IVGN
N/a - $24.76
- 0.00
- $24.76
Invitrogen Corporation engages in the development, manufacture, and marketing of research tools in reagent, kit, and applications forms for the life sciences research, drug discovery, and diagnostics customers, as well as biological products manufacturers

-
SGMO
Sangamo Bioscienc - $6.35
- -0.78%
- $6.37
Sangamo BioSciences, Inc. focuses on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification

-
PPH
Ml Pharma Holdr12 - $62.68
- +0.11%
- $62.45
No Analysis added
- BIO & PHARM's Blog
- No Blogs Found
- Top Professional Portfolios
- 1. Navellier & Associ...
- 2. Fidelity Contrafund - ...
- 3. Argus Management
- 4. WisdomTree Intl Consum...
- 5. Charlie Munger
- show all
- Top Do-It-Yourself Portfolios
- » John Shier
- » Joy
- » tsamanuli Portfolio 1
- » brueckenc Portfolio 1
- » Fundsonly Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Roberto Pedone Posted on Nov. 6, 2009 According to Jim Cramer, the bears are tellinginvestors six lies. On Wednesday’s “Mad Money” TV show, Cramer said if you ...
By Roberto Pedone Posted on Nov. 5, 2009 The traders on CNBC’s “Fast Money” told their viewers what they must know after Warren Buffett announced on Tuesday his l...
By Jonas Elmerraji Posted on Nov. 4, 2009 For investors who seek out short-squeeze opportunities, there’s no time as important as earnings season. Earnings are one of...
By Stockpickr Staff Posted on Nov. 4, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is...
A. The only one I own : SLX,
too hard pick a winner out all of them
Here is a list of some of the biggest stocks that hit 52-week lows on Nov. 2, 2009. more
Analyst Downgrades for Nov. 2, 2009. Read more here. more
Here are some of the biggest stocks that made the 52-week high list on Nov. 2, 2009. more











Comments not available